BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

N30 Pharma to Present S-Nitrosoglutathione Reductase Inhibitor Preclinical Safety Data at 2011 Society of Toxicology 50th Anniversary Meeting


3/2/2011 10:13:21 AM

BOULDER, Colo., March 2, 2011 /PRNewswire/ -- N30 Pharmaceuticals, LLC (N30 Pharma) today announced it will present data at the 2011 Annual Meeting of the Society of Toxicology in Washington, D.C. on Monday, March 7, 2011. The data describe the preclinical safety evaluation of small molecule inhibitors of S-nitrosoglutathione reductase (GSNOR), and the lack of apparent mechanism-based toxicities. GSNOR is a critical enzyme in the endogenous nitric oxide pathway, and its activity is thought to be important in human respiratory, gastrointestinal and cardiovascular disease. N30 Pharma's first GSNOR inhibitor, N6022, is currently in Phase 1b/2a testing. The poster will be available as a PDF on the N30 Pharma website after its presentation (www.n30pharma.com).

Event: 2011 Annual Meeting of the Society of Toxicology

Session Title and Date: Pharmaceutical Safety Assessment: Therapeutic Agents, March 7, 2011, 1 pm EST.

Poster: Inhibition of the Enzyme S-nitrosoglutathione Reductase (GSNOR) Does Not Cause Mechanism-Based Toxicity.

Targeting GSNOR

GSNOR breaks down S-nitrosoglutathione (GSNO), reducing the body's pool of GSNO. In the lung, GSNO likely plays an important role in maintaining normal respiratory function through its influence on bronchial tone and anti-inflammatory effects. Similarly, in the gut, GSNO supports barrier function and maintains the integrity of the gut surface. In asthmatics, GSNOR up-regulation and decreased GSNO levels have been shown to contribute to respiratory disease, and genetic variants of GSNOR have been correlated with disease susceptibility and poor response to therapy. GSNO has also been found to be important in the cardiovascular system as well as the control of breathing.

About inhibitors of GSNOR

N30 Pharma's portfolio of proprietary compounds provides a platform of potent, selective and reversible inhibitors of GSNOR. They increase levels of GSNO, an S-nitrosothiol that plays a central role in health and disease.

SOURCE N30 Pharmaceuticals, LLC



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES